Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride

Oral testosterone undecanoate (TU) is used to treat testosterone deficiency; however, oral TU treatment elevates dihydrotestosterone (DHT), which may be associated with an increased risk of acne, male pattern baldness and prostate hyperplasia. Co-administration of 5α-reductase inhibitors with other...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Androl
Autores principales: Roth, M. Y., Dudley, R. E., Hull, L., Leung, A., Christenson, P., Wang, C., Swerdloff, R., Amory, J. K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4269219/
https://ncbi.nlm.nih.gov/pubmed/20969601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2605.2010.01120.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares